Wall Street analysts forecast that The Medicines Company (NASDAQ:MDCO) will post ($0.77) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for The Medicines’ earnings, with the lowest EPS estimate coming in at ($1.02) and the highest estimate coming in at ($0.63). The Medicines posted earnings of ($1.44) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 46.5%. The business is scheduled to announce its next earnings report on Wednesday, April 25th.
According to Zacks, analysts expect that The Medicines will report full-year earnings of ($2.71) per share for the current financial year, with EPS estimates ranging from ($3.45) to ($2.10). For the next fiscal year, analysts forecast that the business will report earnings of ($2.02) per share, with EPS estimates ranging from ($2.33) to ($1.53). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover The Medicines.
The Medicines (NASDAQ:MDCO) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($2.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.71). The Medicines had a negative return on equity of 316.40% and a negative net margin of 1,035.27%. The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $20.71 million. During the same period in the prior year, the business earned ($1.19) earnings per share. The Medicines’s revenue for the quarter was down 50.6% compared to the same quarter last year.
A number of equities research analysts have commented on the company. BidaskClub raised The Medicines from a “sell” rating to a “hold” rating in a report on Thursday. Oppenheimer set a $50.00 target price on The Medicines and gave the company a “buy” rating in a report on Monday. ValuEngine raised The Medicines from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Zacks Investment Research downgraded The Medicines from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Jefferies Group restated a “buy” rating and issued a $47.00 price target on shares of The Medicines in a research report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $51.00.
The Medicines (NASDAQ:MDCO) traded down $0.20 during trading on Thursday, reaching $34.23. The company’s stock had a trading volume of 112,164 shares, compared to its average volume of 1,595,388. The Medicines has a 12 month low of $24.45 and a 12 month high of $55.95. The company has a current ratio of 3.21, a quick ratio of 3.18 and a debt-to-equity ratio of 26.06. The firm has a market capitalization of $2,548.07, a P/E ratio of -3.46 and a beta of 0.74.
In other news, CEO Clive Meanwell sold 136,250 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $27.24, for a total value of $3,711,450.00. Following the completion of the transaction, the chief executive officer now owns 587,652 shares in the company, valued at $16,007,640.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 8.22% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its position in The Medicines by 33.8% during the 4th quarter. SG Americas Securities LLC now owns 7,145 shares of the company’s stock worth $195,000 after purchasing an additional 1,805 shares in the last quarter. Swiss National Bank increased its position in The Medicines by 1.6% during the 3rd quarter. Swiss National Bank now owns 120,650 shares of the company’s stock worth $4,469,000 after purchasing an additional 1,900 shares in the last quarter. American International Group Inc. increased its position in The Medicines by 3.7% during the 3rd quarter. American International Group Inc. now owns 54,031 shares of the company’s stock worth $2,001,000 after purchasing an additional 1,947 shares in the last quarter. California Public Employees Retirement System increased its position in The Medicines by 1.3% during the 3rd quarter. California Public Employees Retirement System now owns 159,600 shares of the company’s stock worth $5,912,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in The Medicines by 27.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,780 shares of the company’s stock worth $295,000 after purchasing an additional 2,300 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/the-medicines-company-mdco-expected-to-announce-earnings-of-0-77-per-share.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Get a free copy of the Zacks research report on The Medicines (MDCO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.